Sexually Transmitted Infections: A Complete Guide to Prevention, Symptoms, and Treatment

Sexually transmitted infections (STIs), also referred to as sexually transmitted diseases (STDs), represent one of the most significant public health challenges globally. The World Health Organization estimates that more than one million new STIs are acquired every day worldwide, with a substantial proportion going undiagnosed due to stigma, lack of awareness, or asymptomatic presentation.

The consequences of untreated STIs extend well beyond immediate symptoms. They include chronic illness, infertility, increased risk of certain cancers, complications during pregnancy, and — in the case of HIV — life-threatening immunosuppression. Yet the majority of STIs are either fully curable or, when incurable, highly manageable with modern medicine.

This guide is intended as a medically grounded reference for understanding how STIs are transmitted, how to prevent them effectively, what symptoms warrant immediate medical attention, and what treatment options are currently available.

PART 1: UNDERSTANDING SEXUALLY TRANSMITTED INFECTIONS

1.1 What Are STIs?

A sexually transmitted infection is any infection primarily transmitted through sexual contact — including vaginal, anal, and oral sex. Some infections (such as herpes, HPV, and syphilis) can also be transmitted through skin-to-skin contact without penetration. A subset of STIs can be transmitted through blood (sharing needles, blood transfusions) or from mother to child during pregnancy, childbirth, or breastfeeding.

The distinction between "STI" and "STD" is clinically relevant: an infection (STI) exists when a pathogen is present in the body but may not yet cause symptoms or disease. An infection becomes a disease (STD) when it produces clinical symptoms. Many STIs remain asymptomatic for extended periods, which is precisely why regular testing is a cornerstone of sexual health management.

1.2 Categories of STIs by Pathogen Type

STIs are caused by three categories of pathogens:

Bacterial STIs (curable with antibiotics):

Chlamydia
Gonorrhoea
Syphilis
Mycoplasma genitalium

Viral STIs (manageable but not curable with current medicine):

HIV (Human Immunodeficiency Virus)
HPV (Human Papillomavirus)
HSV-1 and HSV-2 (Herpes Simplex Virus)
Hepatitis B and C

Parasitic STIs (curable with antiparasitic medication):

Trichomoniasis (Trichomonas vaginalis)
Pubic lice (Pthirus pubis)
Scabies (Sarcoptes scabiei)

PART 2: HOW STIs ARE TRANSMITTED

Understanding transmission pathways is foundational to effective prevention.

2.1 Primary Routes of Transmission

Transmission Route	Associated STIs
Vaginal, anal, or oral sex	Chlamydia, gonorrhoea, syphilis, HIV, herpes, HPV, trichomoniasis
Skin-to-skin genital contact	Herpes (HSV-1, HSV-2), HPV, syphilis
Blood-to-blood contact	HIV, Hepatitis B, Hepatitis C
Mother to child (vertical)	HIV, syphilis, herpes, gonorrhoea, chlamydia
Contaminated needles or syringes	HIV, Hepatitis B, Hepatitis C
Saliva (limited cases)	HSV-1 (oral herpes), Hepatitis B (rare)

2.2 Risk Factors That Increase Vulnerability

Certain behavioral and situational factors significantly elevate STI risk:

Multiple sexual partners without barrier protection
Inconsistent or incorrect condom use
Prior STI history (past infection increases susceptibility to reinfection and to other STIs)
Substance use that impairs judgement during sexual encounters
Young age — STIs disproportionately affect individuals aged 15–24
Immunosuppression (HIV, chemotherapy, organ transplant recipients)
Lack of access to regular sexual health screening
Transactional sex work without institutional health support

PART 3: SYMPTOMS — RECOGNIZING WARNING SIGNS

A critical and frequently underemphasized fact: many STIs produce no symptoms, particularly in their early stages. An individual may carry and transmit an infection for months or years without awareness. This asymptomatic nature is the primary driver of ongoing transmission in communities.

When symptoms do appear, they vary by infection type.

3.1 Common Symptoms by Infection

Chlamydia Often entirely asymptomatic. When symptoms occur: unusual discharge from the penis or vagina, burning sensation during urination, pain or swelling in the testicles, rectal pain or discharge, cervical inflammation.

Gonorrhoea Thick yellow, white, or green discharge from the penis or vagina; burning urination; sore throat (pharyngeal gonorrhoea); rectal symptoms including discharge, itching, and pain. In women, gonorrhoea frequently causes no symptoms until it progresses to pelvic inflammatory disease (PID).

Syphilis Progresses through four stages:

Primary: A painless ulcer (chancre) at the site of infection — genitals, anus, lips, or mouth — that heals without treatment but the infection persists
Secondary: Widespread rash (often on palms and soles), flu-like symptoms, hair loss, genital warts
Latent: No symptoms; remains infectious in early latency
Tertiary: Severe organ damage affecting the heart, brain, and nervous system if untreated

HIV Acute phase (2–4 weeks post-exposure): Flu-like illness — fever, swollen lymph nodes, sore throat, rash, fatigue, muscle aches. This phase is often misidentified as influenza. Chronic phase: Asymptomatic for years while the virus progressively damages the immune system. Advanced HIV/AIDS: Recurrent severe infections, unexplained weight loss, chronic diarrhoea, neurological symptoms.

Herpes (HSV-1 and HSV-2) Many people with herpes experience no recognizable symptoms. When present: painful blisters or sores on the genitals, buttocks, thighs, or mouth; tingling, itching, or burning before outbreak; flu-like symptoms during the first outbreak; recurrent outbreaks of variable frequency.

HPV (Human Papillomavirus) Most HPV infections are asymptomatic and resolve spontaneously. Certain strains cause genital warts (soft, flesh-coloured growths on the genitals or anus). High-risk HPV strains (particularly types 16 and 18) cause no visible symptoms but are responsible for the majority of cervical cancers, as well as cancers of the anus, penis, throat, and vulva.

Trichomoniasis Up to 70% of cases are asymptomatic. When symptoms occur: frothy, yellow-green vaginal discharge with an unpleasant odour; vaginal itching, burning, redness, and soreness; painful urination; discomfort during sex.

Hepatitis B Acute infection symptoms: fatigue, nausea, abdominal pain, dark urine, jaundice. Chronic infection is often asymptomatic for decades until significant liver damage (cirrhosis, liver cancer) develops.

3.2 When to Seek Immediate Medical Attention

Consult a healthcare provider promptly if you experience:

Any unusual discharge from the genitals or rectum
Sores, ulcers, warts, or unusual growths in the genital area
Burning or pain during urination
Unexplained rash, particularly on the palms, soles, or genitals
Pelvic pain or pain during sex
Swollen lymph nodes in the groin
Flu-like illness within 2–4 weeks of unprotected sexual exposure

Do not wait for symptoms to worsen or assume symptoms will resolve independently. Early intervention is the most effective determinant of treatment outcome.

PART 4: PREVENTION — EVIDENCE-BASED STRATEGIES

4.1 Barrier Methods

Male (External) Condoms When used consistently and correctly, male latex condoms reduce the risk of HIV transmission by approximately 85%, and provide significant protection against gonorrhoea, chlamydia, and trichomoniasis. Protection is lower for infections transmitted via skin-to-skin contact (herpes, HPV, syphilis) because condoms do not cover all potentially infectious skin surfaces.

Correct condom use technique:

Check the expiry date and packaging integrity before use
Use only with water-based or silicone-based lubricants (oil-based lubricants degrade latex)
Pinch the tip to remove air before rolling down the full length
Use a new condom for every sexual act, including between different sexual acts in the same session
Use appropriately sized condoms — condoms that are too loose may slip; those too tight may tear

Female (Internal) Condoms Internal condoms (polyurethane or nitrile) offer similar protection to external condoms and have the advantage of being controlled by the receptive partner. They can be inserted up to 8 hours before intercourse.

Dental Dams Thin latex or polyurethane sheets used as barrier protection during oral-vaginal or oral-anal contact. They reduce transmission risk for herpes, HPV, and syphilis.

4.2 Vaccination

Vaccination is available and strongly recommended for two major STIs:

HPV Vaccine (Gardasil 9) Protects against nine HPV strains responsible for the majority of cervical cancers and genital warts. Recommended for:

All individuals aged 9–26 regardless of gender
Individuals aged 27–45 in consultation with a healthcare provider
Most effective when administered before sexual debut, but provides benefit to sexually active individuals who have not yet been exposed to the specific strains covered

Hepatitis B Vaccine A three-dose vaccine series that provides lifelong protection against Hepatitis B. Recommended for all unvaccinated adults, particularly those with multiple sexual partners, healthcare workers, and intravenous drug users.

Hepatitis A Vaccine While not sexually transmitted in the conventional sense, Hepatitis A can be transmitted through certain sexual practices (oral-anal contact). Vaccination is recommended for MSM (men who have sex with men) and travelers to endemic regions.

4.3 Pre-Exposure Prophylaxis (PrEP) for HIV

PrEP is a daily oral medication (tenofovir/emtricitabine, brand name Truvada or generic equivalents) taken by HIV-negative individuals at high risk of exposure. When taken consistently as prescribed, PrEP reduces the risk of acquiring HIV through sexual contact by approximately 99%.

PrEP is recommended for:

HIV-negative individuals whose sexual partners are HIV-positive
Individuals who do not consistently use condoms with partners of unknown HIV status
People who have had a bacterial STI in the past 6 months
Intravenous drug users who share equipment

PrEP requires a prescription, regular HIV testing (every 3 months), and kidney function monitoring. It does not protect against other STIs.

4.4 Post-Exposure Prophylaxis (PEP) for HIV

PEP is an emergency antiretroviral treatment taken within 72 hours of potential HIV exposure. It must be taken for 28 consecutive days. The sooner it is initiated, the more effective it is. PEP is not intended as a routine prevention strategy — it is an emergency intervention.

Seek PEP immediately following:

Unprotected sex with a person known to be HIV-positive
Condom failure with a partner of unknown HIV status who is high-risk
Sexual assault

4.5 Regular Testing and Partner Communication

The most protective behavioral intervention after condoms is regular, routine STI testing. Testing recommendations vary by individual risk profile:

Risk Profile	Recommended Testing Frequency
Sexually active adults with one consistent partner	Annually
Adults with multiple partners	Every 3–6 months
MSM (men who have sex with men)	Every 3 months
Individuals using PrEP	Every 3 months (mandatory for PrEP prescriptions)
Pregnant individuals	At first prenatal visit; again in third trimester
Following unprotected sex with new partner	At 2 weeks and 6 weeks post-exposure (HIV window period)

Communicating with partners about STI status, testing history, and condom use is both a personal health responsibility and a legal obligation in many jurisdictions (particularly regarding HIV disclosure). Normalizing these conversations is the most effective long-term public health intervention.

4.6 Mutual Monogamy and Reducing Partner Numbers

Consistent mutual monogamy — where both partners have been tested and are exclusive — eliminates sexual transmission risk within the relationship. This requires verified testing before the relationship becomes exclusive, not merely a verbal agreement.

PART 5: DIAGNOSIS — WHAT TESTING INVOLVES

5.1 Types of Diagnostic Tests

STI	Test Type
Chlamydia & Gonorrhoea	Urine sample or swab (genital, rectal, or throat) — NAAT (nucleic acid amplification test)
Syphilis	Blood test (RPR or TPPA); confirmatory treponemal test
HIV	Blood test or rapid oral fluid test; NAAT for acute infection detection
Herpes	Swab of active sore for viral culture or PCR; blood test for antibodies (IgG)
HPV	Cervical Pap smear / HPV co-test (women); no approved test for men
Hepatitis B & C	Blood test for antigens and antibodies
Trichomoniasis	Microscopy or NAAT from vaginal/urethral swab

5.2 Window Periods

Every STI test has a window period — the time between infection and when a test can reliably detect it. Testing during the window period may produce false-negative results.

STI	Window Period
HIV (4th generation antibody/antigen test)	18–45 days
HIV (NAAT)	10–33 days
Chlamydia / Gonorrhoea	1–2 weeks
Syphilis	3–6 weeks
Herpes (HSV IgG blood test)	12–16 weeks
Hepatitis C	8–11 weeks

If testing shortly after a potential exposure, a negative result should be followed by re-testing after the relevant window period has elapsed.

5.3 Where to Get Tested

Sexual health clinics / GUM clinics (most comprehensive and confidential)
General practitioner / family doctor
Planned Parenthood and equivalent reproductive health organizations
At-home testing kits (available for HIV, chlamydia, gonorrhoea, syphilis — postal results)
Hospital emergency departments (for PEP initiation)

PART 6: TREATMENT — CURRENT MEDICAL STANDARDS

6.1 Bacterial STIs (Curable)

Chlamydia First-line treatment: Doxycycline 100mg twice daily for 7 days, or Azithromycin 1g single dose. Re-testing is recommended 3 months after treatment due to high reinfection rates. Partners must be notified and treated simultaneously.

Gonorrhoea Due to the emergence of antibiotic-resistant strains (Neisseria gonorrhoeae), current treatment guidelines typically recommend dual therapy: ceftriaxone 500mg intramuscular injection (or 1g if weight >150kg). Oral azithromycin is no longer recommended as sole therapy due to resistance concerns. Test-of-cure is required 1–2 weeks post-treatment.

Syphilis Primary, secondary, and early latent syphilis: Benzathine penicillin G 2.4 million units, single intramuscular injection. Late latent or tertiary syphilis requires three weekly doses. For penicillin-allergic patients: doxycycline for 14–28 days depending on stage. Neurosyphilis requires intravenous penicillin.

Mycoplasma genitalium Increasingly antibiotic resistant. Current guidelines recommend resistance-guided therapy: doxycycline followed by azithromycin, or moxifloxacin for resistant strains. Resistance testing prior to treatment is now recommended.

6.2 Viral STIs (Manageable, Not Curable)

HIV Antiretroviral therapy (ART) is the standard of care and is initiated immediately upon diagnosis regardless of CD4 count. Modern ART regimens involve one tablet daily (combination therapy). With consistent adherence, individuals with HIV can achieve undetectable viral loads — at which point the virus cannot be sexually transmitted (Undetectable = Untransmittable, or U=U). Life expectancy with early diagnosis and consistent ART approaches that of the general population.

Herpes (HSV-1 and HSV-2) Antiviral medications — acyclovir, valacyclovir, or famciclovir — reduce outbreak frequency, severity, and duration, and reduce (but do not eliminate) transmission risk. Options include:

Episodic therapy: Taken at the onset of an outbreak to shorten duration
Suppressive therapy: Taken daily to reduce outbreak frequency and ongoing transmission risk. Recommended for individuals with frequent outbreaks (6+ per year) or those with HIV-negative partners

HPV No antiviral medication targets HPV directly. The immune system clears most infections within 1–2 years. Treatment is directed at the manifestations:

Genital warts: Topical treatments (podophyllotoxin, imiquimod, sinecatechins); cryotherapy; surgical removal
Cervical cell changes: Detected through regular Pap smears; managed with colposcopy, LLETZ/LEEP, or cryotherapy depending on severity
HPV-related cancers: Managed according to oncological guidelines (surgery, radiation, chemotherapy)

Hepatitis B Acute infection: Supportive care in most cases; the majority of adults clear the infection spontaneously. Chronic infection: Antiviral therapy (tenofovir or entecavir) to suppress viral replication and reduce liver damage progression. Regular liver function monitoring is essential.

Hepatitis C Direct-acting antivirals (DAAs) — sofosbuvir-based regimens, ledipasvir, daclatasvir — have transformed Hepatitis C treatment. A 8–12 week oral course achieves a cure rate exceeding 95% across all genotypes. This represents one of the most significant advances in infectious disease treatment of the past two decades.

6.3 Parasitic STIs (Curable)

Trichomoniasis Metronidazole 500mg twice daily for 7 days, or a single 2g dose. Sexual partners must be treated simultaneously to prevent reinfection. Avoid alcohol during and 24–48 hours after metronidazole use due to disulfiram-like reaction.

Pubic Lice (Crabs) Topical permethrin 1% cream or malathion 0.5% lotion applied to affected areas. All clothing, bedding, and towels should be washed at 50°C+. Sexual contacts within the past month should be treated.

Scabies Permethrin 5% cream applied from neck to toes, left overnight, and rinsed. A second application is required one week later. All household and close physical contacts must be treated simultaneously regardless of symptoms.

PART 7: SPECIAL POPULATIONS AND CONSIDERATIONS

7.1 STIs During Pregnancy

Untreated STIs during pregnancy carry serious risks for both mother and child:

Syphilis: Can cause congenital syphilis — stillbirth, low birth weight, bone deformities, neurological damage. Treatable with penicillin during pregnancy.
HIV: Without intervention, mother-to-child transmission risk is 15–45%. With ART during pregnancy and postpartum, risk is reduced to below 1%.
Gonorrhoea and Chlamydia: Can cause neonatal eye infections (ophthalmia neonatorum) and pneumonia. Treated with antibiotics.
Herpes: Neonatal herpes, acquired during vaginal delivery when active lesions are present, is rare but can be fatal. Caesarean section is recommended when active genital herpes lesions are present at onset of labor.
HPV: Genital warts can enlarge during pregnancy. Rarely, recurrent respiratory papillomatosis in the newborn can result from maternal HPV infection.

All pregnant individuals should be screened for HIV, syphilis, hepatitis B, chlamydia, and gonorrhoea at the first prenatal visit.

7.2 STIs in Adolescents

Young people aged 15–24 account for approximately half of all new STI diagnoses globally, despite representing a fraction of the sexually active population. Contributing factors include lower likelihood of condom use, higher frequency of partner change, biological susceptibility (cervical ectopy in adolescent females), and reduced access to confidential healthcare.

Comprehensive sex education — including STI prevention, contraception, consent, and healthy relationship communication — has a demonstrated evidence base for reducing STI incidence and unintended pregnancy in adolescent populations.

7.3 STIs and Mental Health

An STI diagnosis — particularly for stigmatized infections such as HIV or herpes — frequently generates significant psychological distress: shame, anxiety, depression, and disruption to sexual identity and relationships. This response is normal and does not reflect the actual severity of the medical condition.

Healthcare providers should routinely address the psychological dimensions of STI diagnosis. Counselling, peer support groups, and psychoeducation about the medical reality of the infection (particularly U=U for HIV, and the near-universal prevalence of HSV) are valuable components of holistic care.

PART 8: REDUCING STIGMA — A PUBLIC HEALTH IMPERATIVE

STI stigma is not merely a social problem — it is a clinical one. Fear of judgement prevents individuals from getting tested, disclosing to partners, and accessing treatment. This perpetuates transmission chains far more effectively than any pathogen.

The medical consensus is clear: STIs are common health conditions, not indicators of moral failure or reckless behavior. Anyone who is sexually active is potentially at risk. The appropriate response is testing, treatment, and prevention — not shame.

Healthcare providers have a professional responsibility to create non-judgmental clinical environments. Patients have the right to honest, confidential, non-stigmatizing care.

Summary: Prevention and Treatment at a Glance

STI	Curable?	Primary Prevention	Primary Treatment
Chlamydia	✅ Yes	Condoms	Doxycycline / Azithromycin
Gonorrhoea	✅ Yes	Condoms	Ceftriaxone (IM injection)
Syphilis	✅ Yes	Condoms	Benzathine Penicillin G
Trichomoniasis	✅ Yes	Condoms	Metronidazole
HIV	❌ Manageable	Condoms + PrEP	Antiretroviral Therapy (ART)
Herpes (HSV)	❌ Manageable	Condoms + antivirals	Acyclovir / Valacyclovir
HPV	❌ Manageable	Vaccination + condoms	Treat manifestations
Hepatitis B	❌ Manageable (acute often resolves)	Vaccination	Tenofovir / Entecavir
Hepatitis C	✅ Yes (>95% cure rate)	Harm reduction	Direct-acting antivirals

Conclusion

Sexually transmitted infections are among the most common medical conditions affecting sexually active individuals globally. They are also among the most preventable and, in many cases, the most treatable. The gap between this medical reality and widespread public understanding is sustained almost entirely by stigma and inadequate education.

The foundation of sexual health is straightforward: use barrier protection consistently and correctly, vaccinate against HPV and hepatitis B, test regularly according to your risk profile, communicate openly with partners, and seek medical care promptly when symptoms arise or exposure occurs.

No individual should allow shame or fear to delay diagnosis or treatment. The health consequences of untreated STIs compound over time — while the consequences of testing and treatment are overwhelmingly positive.

This article is intended for educational purposes and does not constitute individualized medical advice. Consult a qualified healthcare provider for diagnosis, testing, and treatment tailored to your specific situation. Treatment guidelines evolve as resistance patterns change; always defer to current national and WHO guidelines.